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Abstract
Background: A post-operative pancreatic fistula (POPF) is a major cause of morbidity and mortality
after a pancreaticoduodenectomy (PD). This systematic review aimed to identify all scoring systems to
predict POPF after a PD, consider their clinical applicability and assess the study quality.
Method: An electronic search was performed of Medline (1946–2014) and EMBASE (1996–2014) data-
bases. Results were screened according to Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines, and quality assessed according to the QUIPS (quality in prognos-
tic studies) tool.
Results: Six eligible scoring systems were identified. Five studies used the International Study Group
on Pancreatic Fistula (ISGPF) definition. The proposed scores feature between two and five variables
and of the 16 total variables, the majority (12) featured in only one score. Three scores could be fully
completed pre-operatively whereas 1 score included intra-operative and two studies post-operative
variables. Four scores were internally validated and of these, two scores have been subject to subse-
quent multicentre review. The median QUIPS score was 38 out of 50 (range 16–50).
Conclusion: These scores show potential in calculating the individualized patient risk of POPF. There
is, however, much variation in current scoring systems and further validation in large multicentre
cohorts is now needed.
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Introduction
A pancreaticoduodenectomy (PD) remains the operation of
choice for the majority of malignant and benign neoplasms of
the head of the pancreas and periampullary region. Despite the
centralization of PD to high-volume tertiary centres resulting
in a reduction in mortality from 14% to 2%,1–4 post-operative
morbidity remains significant at 30–50%.5
A post-operative pancreatic fistula (POPF) occurs in 5–30%
of patients.6 This is associated with serious sequelae including
sepsis, haemorrhage and death, with resulting prolonged hospi-
tal stays and increased healthcare costs.1,6 The incidence of
POPF has remained fairly constant over the past 30 years even
in experienced centres.7,8
The risk factors for POPF have been extensively analysed
and published,2,5,6,9–14 more recently abetted by the wide
acceptance of the POPF definition from the International
Study Group on Pancreatic Fistula (ISGPF).5 Based on these
risk factors, a number of groups have now proposed the use of
predictive scores to stratify a patient’s risk of developing a
POPF. A predictive score would allow clinicians to consent
accurately patients on their individual risk of developing a
POPF, as well as directing post-operative management such as
early drain removal and, therefore, promoting enhanced
recovery.
The aim of this systemic review was to identify all scoring
systems proposed to predict the likelihood of a POPF after a
PD, consider their clinical applicability and assess the study
quality.
This study was presented at the Pancreatic Society Annual Meeting, 27-
29 November 2014, Guildford, UK and the 11th Congress of the E-
AHPBA, 21-24 April 2015, Manchester, UK.
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Methods
Study design and identification
A search strategy was designed to identify all clinical studies
proposing a score to predict the likelihood of a POPF after a
PD. An electronic search was performed of the MEDLINE and
EMBASE database for the period 1946 (MEDLINE) and 1996
(EMBASE) to December 2014. The references from the
included studies were searched to identify additional studies.
Records extracted by the initial search were screened, and
potentially relevant papers were retrieved and assessed in more
detail according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidance.15 Eligibil-
ity assessment was performed by two authors (A.E.V. and
A.L.Y.) independently. Any disagreement over study inclusion
was resolved by discussion with the senior author (A.M.S.).
The following search strategy was used (pylorus preserv* OR
Whipple* OR pancreat* resection, pancreatojejunostom* OR
pancreatoduodenectomy* OR pancreaticoduodenectom* OR
duodenopancreatectom*, pancreatectom*) AND [(risk assess-
ment OR scoring system OR prognostic score OR decision
support techniques) OR (pancrea* fistula OR pancrea* leak
OR anastomotic leak)].
Inclusion criteria
Studies were included if they proposed a novel scoring system to
predict the development of POPF. The search was limited to
English-language publications in human subjects. Only studies
exclusively investigating PD in adult patients (aged ≥18 years)
were included. The minimum data necessary for inclusion was
a description of POPF definition and the proposed scoring
system.
Exclusion criteria
Abstracts (such as those published as part of conference pro-
ceedings), reviews and case reports were excluded as were stud-
ies including additional types of pancreatic resection in the
modelling database.
Quality assessment and data extraction
The quality of each study was assessed using the QUIPS (quality
in prognosis studies) tool.16 This involves the scoring of five
domains of potential bias (study participation, prognostic factor
measurement, outcome measurement, confounding factor mea-
surement and analysis) according to whether it is quality limits
potential bias. A score of 2 indicates that it does; a score of 1
indicates that it does so ‘partly’, and a score of 0 indicates that it
does not. Data were extracted independently by the authors and
disagreements resolved by discussion with the senior author.
Results
Search results
The electronic search yielded 2082 hits in MEDLINE and
3345 hits in EMBASE and is detailed in Fig. 1. A total of six
studies met the eligibility criteria and were included in the
review.
Summary of selected study characteristics
All six studies were published since 2009. These studies
(3 from Europe, 1 Asia and 2 USA) utilized retrospective data
from a single institution over a period of 1–5 years and
included between two and five variables in the eventual pro-
posed score. Sixteen variables in total were proposed with one
variable (age) present in two scores and three variables [body
mass index (BMI), pancreatic duct width and pathological
diagnosis] present in three scores. Three scores could be calcu-
lated from pre-operative variables alone whereas one required
intra-operative variables and two included post-operative
variables.
The median number of patients included in the score mod-
elling group in each study was 172 (range 62–279) and the
median rate of POPF in the modelling databases was 31%
(range 22–53%). Five studies used the ISGPF definition of
POPF of which three included all grades whereas the remain-
ing two included only Grades B and C. There was no valida-
tion performed in two studies, whereas in four studies the
dataset was divided into a derivation and validation set to per-
form internal validation. In two studies, the scoring system has
subsequently been applied to an external patient cohort.
Table 1 summarizes the scoring systems predicting a POPF
after a PD and Table 2 details the variables included in each of
these studies.
Pre-operative models
Wellner (2010)
The score from Wellner et al. was formed by first establishing
peri-operative predictors of POPF and extrapolating these to
devise a score that may be completed pre-operatively.17 A his-
tory of weight loss and soft pancreatic texture (as measured
intra-operatively) were found to predict strongly a POPF. Sub-
sequent univariate analysis demonstrated age less than 66 years
and a history of acute pancreatitis or smoking independently
predicted a firm pancreatic texture. The final POPF score,
therefore, included these pre-operative predictors of texture.
The final score allowed patients to be subdivided into low-,
moderate- or high-risk groups for POPF. When the score was
internally validated, the incidence of POPF significantly corre-
lated with each of the three patient risk groups (correlation
coefficient r = 0.35).
Yamamoto (2011)
The score proposed by Yamamoto et al. included patient gender
and four measurements from pre-operative CT images: the main
pancreatic duct (MPD) index (defined as the ratio of the diame-
ter of MPD to the diameter of the short axis of the pancreatic
body), relation of the portal vein to the tumour (attached/ com-
pressed/ involved), intra-abdominal fat thickness and a diagnosis
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other than pancreatic cancer.18 Variables were assigned a value
based on the magnitude of the beta-coefficients identified from
the regression analysis. A stratum-specific likelihood ratio
(SSLR), which indicates to what degree a diagnostic test result
increases or decreases the pre-test probability of POPF,19 showed
that the SSLR values at the score extremes indicated moderate to
large changes in the likelihood of POPF.
Roberts (2014)
Roberts et al. constructed a score based on only two variables,
body mass index (BMI) and the pre-operative radiological
measurement of the pancreatic duct width.20 The score has been
made available online (http://www.uhb.nhs.uk/preoperative-
prediction-of-pancreatic-fistula-calculator.htm). The authors found
that patients with a pancreatic duct of >10 mm regardless of
BMI, have a risk of <5% and patients with a BMI of 30–35 kg/m2
with a pancreatic duct <3 mm have a 30–55% risk of POPF.
This score was subsequently externally validated upon a multi-
centre cohort.21 Attempts to improve the score were not possi-
ble, despite the inclusion of intra- or post-operative variables.
The score demonstrated a significant stepwise increase with
more severe types of POPF.
Medline database search n = 2082  Embase database search n = 3345
Duplicates excluded n = 1378 
Potential relevant studies identified 
and screen for retrieval n = 4049 
Studies excluded n = 4021 
 Review articles n = 412 
 Non-humans n = 269 
 Non- English n = 370 
Case reports n = 588 
No scoring system proposed n = 2382 
Full-text articles reviewed n = 28 
Studies included in review n = 6 
Studies excluded n = 22 
No scoring system proposed n = 13 
Other procedure included (e.g. distal 
pancreatectomy) n = 3 
General morbidity (not exclusively POPF) 
n = 6 
Figure 1 Search strategy used to identify included studies
Table 1 Current published scoring systems predicting POPF following PD
Author and year
of publication
(Time period of
data collection)
Patients in
modelling
cohort
Outcome of
interest
Proportion of
modelling
cohort
developing
outcome (%)
Proposed
score
scale
Predicative
accuracy
Internal
validation –
predictive
accuracy (N)
External
validation –
predictive
accuracy (N)
Gaujoux et al.25
2004–2005
100 ISGPF grade
A–C and B–C
31 (31) A–C
27 (27) B–C
0–3 AUC 0.78 (A–C)
AUC 0.81 (B–C)
Not done Not done
Wellner et al.17
2006–2008
62 ISGPF
grade A–C
19 (31) 3 to 2 SR correlation
coefficient = 0.47
SR correlation
coefficient =
0.35 (279)
Not done
Yamamoto et al.18
2004–2009
279 ISGPF
grade B–C
103 (37) 0–7 AUC 0.810 AUC 0.808 (108) Not done
Callery et al.22
2002–2007
233 ISGPF
grade A–C
58 (24.7)
A–C
0–10 Not stated AUC 0.942 (212) AUC 0.716 (594)
AUC 0.763 (265)
Graham et al.26
2007–2012
146 Drain amylase >39
normal serum
amylase
on or after
POD 4
50 (34) Continuous
0–100%
72% sensitivity
81.3% specificity
Not done Not done
Roberts et al.20
2007–2012
217 ISGPF grade A–C 48 (22.1) Continuous
0–100%
AUC 0.832 AUC 0.751 (108) Score predictive
(P < 0.001) (630)
SR, Spearman rank; AUC, area under curve.
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Intra-operative models
Callery (2013)
Callery et al. devised a score selected from three potential
models, each examined prospectively on a validation cohort.22
The intra-operative assessment of gland texture (firm/ soft)
and pancreatic duct diameter (as measured with a scale at the
cut surface), pre-operative diagnosis and blood loss were
included as score components. Variables in Model I were
weighted equally which was felt to be overly simplistic and,
therefore, Model II assigned points according to the magnitude
of the beta-coefficients identified from the regression analysis.
This model allowed pancreatic duct diameter and intra-opera-
tive blood loss to be analysed as continuous variables although
the complexity was felt to act potentially as a barrier to wide-
spread use. Model III, resembling model II but designed to be
more practical with a scale of 0–10, also demonstrated the best
performance in internal validation. No patient with a score of
0 developed POPF whereas all patients with scores of 9–10
developed clinically relevant POPF. This score has since been
applied to two external patient cohorts. Millers group (2014)
scored 594 patients from three institutions, finding the fistula
risk score to correlate with grade B and C POPF development
(P < 0.001) with an area under the curve (AUC) of 0.716.23
Kunstman et al. calculated this fistula risk score for 265 PD
patients and demonstrated a 1.6-fold increase in grade B and
C POPF per 1-point increase in risk score, a negative predic-
tive value of 100% in patients with a low score (<3) and a sim-
ilar AUC of 0.763.24 However, of the patients with a high
score7–10 only 29% (Miller) and 16.7% (Kunstman) developed
a POPF.
Post-operative models
Gaujoux (2009)
Gaujoux et al. were the first group to propose a predictive
scoring system.25 They identified that a BMI ≥25 kg/m2, the
absence of pancreatic fibrosis and the presence of fatty pan-
creas were significant predictors on multivariable logistic
regression analysis of POPF.25 Pancreatic steatosis and fibrosis
were examined histologically by independent and blinded
assessors. The proposed score was based on the number of
risk factors present (0–3). No further validation was
performed.
Graham (2013)
The score devised by Graham et al. is another available to use
online (http://georgetowncriteria.tumblr.com/).26 Beta-coeffi-
cients from the covariates (age, BMI, post-operative day 2
drain amylase and the intra-operative measure of pancreatic
duct diameter) were formed to devise a formula to predict the
likelihood of POPF. This model was optimized to give an opti-
mum balance of sensitivity to specificity on the author’s
original dataset but no further validation occurred.
Quality assessment
The median QUIPS score for the included studies was 38.5
(range 16–45) (Table 3). The domain at the highest risk of bias
Table 2 Variables included in each score with the total number of appearances in the right column. White background denotes pre-
operative variables, light grey intra-operative variables and dark grey post-operative variables
Wellner et al.
(2010) (17)
Callery et al.
(2013) (22)
Roberts et al.
(2014) (20)
Gaujoux et al.
(2009) (25)
Yamamoto et al.
(2011) (18)
Graham et al.
(2013) (26)
Total
Age   2
Gender  1
Smoking history  1
BMI    3
Weight loss  1
IA fat thickness  1
Pancreatitis history  1
Relation of PV to tumour  1
Diagnosis    3
PD width (radiological)    3
Blood loss  1
Pancreatic texture  1
PD width (intra-operative)  1
Pancreatic fat  1
Pancreatic fibrosis  1
Drain amylase (POD2)  1
BMI, body mass index; IA, intra-abdominal; PV, portal vein; PD, pancreaticoduodenectomy; POD, post-operative day.
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was confounding factor measurement with a median score of 8
out of a possible 14 (range 1–12).
Discussion
Clinical application
Risk stratification tools systematically classify patients to a level
of risk and have an established role in modern surgical prac-
tice, heralded by the widespread use of the American Society
of Anesthesiologists (ASA) grading system.27,28 Scores have
been developed to predict the general risk of peri-operative
morbidity and mortality after pancreatic surgery. These include
the Nebraska Nomogram,29 the John Hopkins mortality
model30 and the HPB risk calculator,3 and a degree of risk
stratification occurs routinely in many institutions by the use
of exercise testing such as cardiopulmonary exercise testing
(CPET).31,32 Although these scores may act as a general
guide to the clinician they are not applicable to individual
complications.
In the era of patient centred care, strategies to quantify the
risk of a POPF after a PD are highly desirable. The systems by
Yamamoto, Wellner and Roberts comprise of easily measurable
radiological and demographic variables and may be con-
structed pre-operatively.17,18,20 Pre-operative risk stratification
has certain advantages including the opportunity to individual-
ize patient consent. Whether this information would affect
patient or clinician decisions to proceed then or not with sur-
gery is not known. Although it is thought that a surgeon’s ‘gut
feeling’ performs equally accurately to existing models of
Table 3 Quality assessment of included studies according to the quality in prognosis studies (QUIPS) tool
Median quality score (range) Maximum score
Study participation 9.5 (2–10) 10
Population described for key characteristics 2 2
Sampling and recruitment described 2 2
Inclusion/exclusion criteria described 2 2
Adequate participation 2 2
Baseline study sample described 2 2
Prognostic factor measurement 8 (5–10) 12
Prognostic factors are clearly described or defined 1.5 2
Continuous variables reported, or appropriate cut-off points used 1.5 2
Prognostic factors are valid and reliable 2 2
Study sample has complete data for prognostic factors 2 2
Same method and setting of measurement for all study participants 2 2
Appropriate methods used for missing prognostic data 0 2
Outcome measurement 6 (5,6) 6
Definition of the outcome described 2 2
Outcome measure and method are valid and reliable 2 2
Same method and setting of measurement for all study participants 2 2
Confounding factor measurement 8 (1–12) 14
Important confounders are measured 1 2
Clear definitions of confounders described 2 2
Measurement of all confounders is valid and reliable 1 2
Same method and setting of measurement for all study participants 1.5 2
Appropriate methods used for missing confounder data 0 2
Important confounders accounted for in the study design 1.5 2
Important confounders accounted for in the analysis 1 2
Analysis 6 (3–8) 8
Sufficient presentation of data to assess the adequacy of the analysis 1.5 2
Strategy for model building appropriate and based on a conceptual model 1.5 2
Adequate selection of model for the design of the study 2 2
No selective reporting of results 2 2
Median quality score of studies 38 (16–45) 50
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morbidity, predictive models can add objectivity to these deci-
sions.33 These scores highlight that the risk of POPF is very
strongly modified by patient variables. There are also clear aca-
demic applications of pre-operative risk scores. Most studies
reviewing the impact of various interventions have failed to
demonstrate a significant reduction in POPF with the proposed
treatments. If patients with a predicted low risk of POPF were
to be excluded from clinical trials, the numbers of participants
needed within the study could be lowered while increasing the
likelihood of observing a treatment effect. In addition, under-
standing a patient’s risk of POPF may inform resource plan-
ning for the health care provider. The management of a
patient with a grade C fistula will cost around six times more
than a patient with no complications after PD ($119053 and
$18075, respectively).1
The technique of pancreatic reconstruction is not included
in any score reflecting current evidence that fails to demon-
strate consistently the optimum reconstructive technique of a
pancreatoenterostomy.34 Furthermore, evidence of the impact
of other interventions, such as internal or external pancreatic
stents and octreotide, upon POPF is conflicting (suggesting
that patient-related factors are more critical in the causation
of POPF.35–41 With the absence of effective strategies to
decrease POPF, it can be argued that these prognostic scores
have no clinical usefulness. However, although recent evidence
suggests that drains should not be omitted post-operatively
even in low-risk patients, these patients may be suitable for
early drain removal.42,43 This has been shown to reduce intra-
abdominal infections in patients without symptoms of
POPF,44,45 allowing for expedited mobilization to potentially
reduce the length of stay thus forming part of an enhanced
recovery programme.45,46 Callery’s group advocate placement
of at least two post-operative drains in patients who accrue a
high intra-operative risk score and may omit drains altogether
in patients with a low fistula risk score.22 They also consider
the use of feeding jejunostomy tubes in elderly patients with a
moderate-to-high post-operative risk score.22 The score by
Graham et al., who take a conservative approach to the man-
agement of POPF by instigating at least 4 weeks of drainage
and parenteral nutrition, may be valuable in managing patient
expectation with regard to length of stay and the start of adju-
vant therapy.26
Risk stratification of a POPF may have a role in facilitat-
ing training opportunities. A PD is considered one of the
most technically demanding surgical procedures and is a
challenging operation for both trainers to teach and trainees
to learn.47,48 Recognizing patients at a lower risk of POPF
may permit the trainee to perform the pancreatoenteric
anastomosis, and conversely an experienced pancreatic sur-
geon may choose to construct this anastomosis in a high-
risk patient. In addition, the adoption of a reliable tool to
calculate individual patient risk would establish surgical
performance more accurately by allowing a correction to be
made for centres and surgeons that treat more high-risk
patient groups.
Extrapolating intra-operative variables to form a
pre-operative score
A soft pancreas is a widely accepted risk factor for POPF6,9,49–
51 and if it were not an intra-operative measurement would
likely feature more prominently in predictive scoring systems.
The relationship between pancreatic texture and other covari-
ables is used in the pre-operative score proposed by Wellner
et al. which utilized factors related to gland texture as surro-
gate risk factors for POPF.17
Pancreatic steatosis has been independently implicated in the
development of POPF25,50 as well as being associated with a
high BMI and increasing age.25,51,52 Despite featuring in the
score by Ganjoux et al., the clinical application of including
the histologically measured pancreatic fat infiltration in a pre-
dictive scoring system is limited. The radiological quantifica-
tion by pancreatic steatosis via computerized tomography
(CT),53 magnetic resonance imaging (MRI)54,55 and ultrasound
(US)56 has shown promise although none of the scores utilize
these assessments.
Pancreatic duct width is strongly (inversely) related to POPF
risk6,11,17,57–59 and was included in over half the scoring sys-
tems reviewed. Pre-operative measurement using CT was uti-
lized in three scores11,20 and intra-operative assessment in 1.22
Using an intra-operative measurement of pancreatic duct width
has not been shown to increase the accuracy of POPF predic-
tion as demonstrated when substituted for the pre-operative
radiological measurement in the scoring system by Roberts
et al.21 Yamamoto et al. found the MPD index to be the stron-
gest predictor of the occurrence of POPF and Callery et al.
report each 1 mm decrease of the pancreatic duct width to
result in a 76% increase in the likelihood of developing
POPF.11,22 Roberts et al. suggests that PD width should be
considered as a continuous variable as considering duct width
as narrow or wide (usually based on a cut off of 3 mm) under-
plays the significant association between duct width and POPF.
They also report a strong correlation between the pre-operative
radiological interpretation of pancreatic duct width by surgeons
and hepatobiliary radiologists suggesting this measurement
could be easily and accurately performed in the outpatient
setting.20
Radiological prediction
With the average PD patient undergoing at least one pre-operative
radiological investigation in conjunction with amulti-disciplinary
team review of these images, the use of imaging as a compo-
nent of pre-operative fistula prediction appears to be ideal.
The utility of CT to predict the occurrence of POPF has been
recently reported57,60,61 and imaging forms a key component
of the score proposed by Yamamoto et al. where four of five
variables are radiological findings.18
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Further scores to predict POPF
Additional scores have been proposed to predict POPF in
patients undergoing a general, pancreatic resection. These
authors include a distal pancreatectomy, middle pancreatec-
tomy and partial resections in the modelling cohorts. Belyaev
et al. proposed a score based on histomorphological features of
the pancreatic remnant62 and Fujiwara et al. proposed a post-
operative inflammatory score based on serum albumin and
c-reactive protein on day one after a resection.63 In addition,
several authors have examined the use of pre-established prog-
nostic indicators in predicting POPF including CPET testing64
and the surgical Apgar score,31 demonstrating a low and high
result, respectively, to be associated with POPF.
Quality assessment and study limitations
The quality of included studies was variable, and two studies
failed to describe the baseline characteristics of the modelling
population adequately. All studies when appropriate attempted
to limit bias by blinding radiology and histology assessors to
patient outcome; however, other sources of potential bias, such
as the subjective nature of the assessment of texture of the
pancreatic gland intra-operatively were not controlled. There
was also a disparity in the use of continuous variables with
sometimes no justification into the cut-off values used in the
conversion of continuous to categorical values. Two scoring
systems lacked internal validation so the reproducibility of
these scores, even in a similar patient cohort (as applied in the
remaining four studies), is not known. Frequently the use of
potential confounders such as octreotide and stents was not
adequately described, accounting for the low overall scores in
this bias assessment domain.
The use of non-independent variables in the scores raises
the issue of multicollinearity. Multicollinearity can increase the
variance of the coefficient estimates and make the estimates
very sensitive to minor changes in the model.65 Both BMI and
pancreatic fat that are known to be closely correlated are
included in the score by Ganjoux et al.25,50,66 The score pro-
posed by Callery et al. again includes non-independent vari-
ables such as pancreatic duct width and gland firmness.21,22
Despite the majority of studies analysing similar variables in
the initial analysis, there were inconsistencies in those identi-
fied as independent predictors of POPF and, therefore,
included in the final score. Although there is no doubt that
POPF is a multifactorial condition, the disparities between the
proposed scoring systems suggest that particular variables may
be more significant in certain patient cohorts than others.
Sample size may account for these differences as although sev-
eral studies included a large number of patients, the actual
number of these patients who developed POPF, particularly
when split into subgroups based on fistula grade, was often
small. Also, institutional differences in patient selection, surgi-
cal technique and post-operative management may account for
these differences between patient cohorts.
Conclusion
These six scores demonstrate a variation in approach to predict
POPF. The prospective validation of these scores in a large
external multicentre cohort is now required to allow direct
comparison of score validity. Although individualized patient
complication prediction after a PD is in the development stage,
an individualized assessment of the risk of POPF is now possi-
ble and may be used as part of informed consent.
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